Novo Nordisk is gearing up to submit its rare blood disorder drug to the FDA after the former Forma Therapeutics asset ...

SCD is a fund I've provided coverage on quite regularly as it's a unique fund. The fund carries a portfolio of MLPs and tech as its largest weightings though it is somewhat diversified overall, too, ...

A new report based on patient focus groups suggests many clinicians can do more to help patients with sickle cell disease (SCD) feel heard and understood. People with sickle cell disease (SCD) say a ...

After decades of limited progress in the treatment of sickle cell disease (SCD), both patients and physicians are on the verge of monumental change. On Friday, the Food and Drug Administration ...

AGIO shares plunge after Novo Nordisk's strong sickle cell data raised doubts about mitapivat's competitiveness and approval ...

A new, validated model for predicting the risk of sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM) has been published. For every 16 patients who receive an implantable ...

Heightened market volatility presents unique buying opportunities for income investors, particularly in the technology and energy sectors, which show signs of bottoming as Q1 earnings season ...